MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jad.2019.11.086

Медицинская библиотека · Journal of affective disorders · 2019

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.

Correia-Melo Fernanda S, Leal Gustavo C, Vieira Flávia, Jesus-Nunes Ana Paula, Mello Rodrigo P, Magnavita Guilherme, Caliman-Fontes Ana Teresa, Echegaray Mariana V F, Bandeira Igor D, Silva Samantha S, Cavalcanti Diogo E, Araújo-de-Freitas Lucas, Sarin Luciana M, Tuena Marco A, Nakahira Carolina, Sampaio Aline S, Del-Porto José A, Turecki Gustavo, Loo Colleen, Lacerda Acioly L T, Quarantini Lucas C

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАEquivalence TrialПеревод пока не подготовлен

Аннотация

BACKGROUND

Ketamine and its enantiomers have recently been highlighted as one of the most effective therapeutic options in refractory depression. However, racemic ketamine and esketamine have not been directly compared. The aim of this study is to assess the efficacy and safety of esketamine compared to ketamine in patients with treatment-resistant depression (TRD).

METHODS

This is a randomized, double-blind, active-controlled, bicentre, non-inferiority clinical trial, with two parallel groups. Participants were randomly assigned to a 40-min single intravenous infusion of ketamine 0.5 mg/kg or esketamine 0.25 mg/kg. The primary outcome was the difference in remission rates for depression 24 h following intervention using the Montgomery-Åsberg Depression Rating Scale (MADRS), with a non-inferiority margin of 20%.

RESULTS

63 subjects were included and randomly assigned (29 to receive ketamine and 34 to receive esketamine). At 24 h, 24.1% of participants in the ketamine group and 29.4% of participants in the esketamine group showed remission, with a difference of 5.3% (95% CILB -13.6%), confirming non-inferiority. MADRS scores improved from 33 (SD 9.3) to 16.2 (SD 10.7) in the ketamine group and from 33 (SD 5.3) to 17.5 (SD 12.2) in the esketamine one, with a difference of -5.27% (95% CILB, -13.6). Both groups presented similar mild side effects.

CONCLUSIONS

Esketamine was non-inferior to ketamine for TRD 24 h following infusion. Both treatments were effective, safe, and well tolerated.

TRIAL REGISTRATION: Registered in Japan Primary Registries Network: UMIN000032355.

Для цитирования: Correia-Melo Fernanda S, Leal Gustavo C, Vieira Flávia, Jesus-Nunes Ana Paula, Mello Rodrigo P, Magnavita Guilherme, Caliman-Fontes Ana Teresa, Echegaray Mariana V F, Bandeira Igor D, Silva Samantha S, Cavalcanti Diogo E, Araújo-de-Freitas Lucas, Sarin Luciana M, Tuena Marco A, Nakahira Carolina, Sampaio Aline S, Del-Porto José A, Turecki Gustavo, Loo Colleen, Lacerda Acioly L T, Quarantini Lucas C. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.. Journal of affective disorders. 2019. DOI: 10.1016/j.jad.2019.11.086.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.